ClinicalTrials.Veeva

Menu

Neuropeptides in the Humane Intra- og Extracerebral Circulation.

D

Danish Headache Center

Status

Completed

Conditions

Healthy
Migraine

Treatments

Drug: sumatriptan

Study type

Interventional

Funder types

Other

Identifiers

NCT00399633
Neuropeptide2007

Details and patient eligibility

About

The study aim at examining whether Sumatriptan changes the plasma values of the neuropeptides vasoactive intestinal polypeptide (VIP), calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase activating peptide (PACAP) and the prostanoids 6-keto-PGF1α, and PGE2, PGD2 og PGF2α.

Full description

The study is meant to give a better understanding of the basic mechanisms behind migraine, and a better understanding of the effects of sumatriptan on the trigemino vascular system.

The endpoints are changes in the plasma values of the neuropeptides vasoactive intestinal polypeptide (VIP), calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase activating peptide (PACAP) and the prostanoids 6-keto-PGF1α, and PGE2, PGD2 og PGF2α.

Enrollment

16 patients

Sex

All

Ages

18 to 50 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • healthy volunteers
  • 18-50 years,
  • 50-100 kg.
  • Fertile women must use birth control.

Exclusion criteria

  • All primary types of headache
  • Daily intake of medicine except birth control
  • Pregnancy
  • Hypertension
  • Hypotension
  • other chronic disease

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems